

1 **Resistance risk assessment of the novel complex II inhibitor pyflubumide in the polyphagous pest**

2 ***Tetranychus urticae***

3 Seyedeh Masoumeh Fotoukkiaii<sup>1</sup>, Catherine Mermans<sup>2</sup>, Nicky Wybouw<sup>2</sup> and Thomas Van Leeuwen<sup>2</sup>

4

5 <sup>1</sup> Department of Evolutionary and Population Biology, Institute for Biodiversity and Ecosystem  
6 Dynamics, University of Amsterdam, Amsterdam, the Netherlands

7 <sup>2</sup> Laboratory of Agrozoology, Department of Plants and Crops, Faculty of Bioscience Engineering,  
8 Ghent University, Coupure Links 653, B-9000 Ghent, Belgium

9

10 Corresponding author:

11 Thomas Van Leeuwen

12 Laboratory of Agrozoology

13 Department of Plants and Crops

14 Faculty of Bioscience Engineering

15 Ghent University

16 Coupure Links 653, B-9000 Ghent, Belgium

17 Phone: +3292646143

18 Email: thomas.vanleeuwen@ugent.be

19

20 **Abstract**

21 Pyflubumide is a novel selective carboxanilide acaricide that inhibits mitochondrial complex II of

22 mainly spider species such as *Tetranychus urticae*. We explored the baseline toxicity and potential cross-

23 resistance risk of pyflubumide in a reference panel of *T. urticae* strains resistant to various acaricides

24 with different modes of action. A cyenopyrafen resistant strain (JPR) was identified as the only strain

25 with low-to-moderate level of cross-resistance to pyflubumide ( $LC_{50} = 49.07$  mg/L). In a resistance risk

26 assessment approach, JPR was subsequently selected which lead to two highly resistant strains JPR-R1

27 ( $LC_{50} = 1437.48$  mg/L) and JPR-R2 ( $LC_{50} = 1893.67$  mg/L). Interestingly, compared to adult females,

28 resistance was much less pronounced in adult males and eggs of the two JPR-R strains. In order to

29 elucidate resistance mechanisms, we first sequenced complex II subunits in susceptible and resistant

30 strains, but target-site insensitivity could not be detected. In contrast, synergism/ antagonism

31 experiments strongly suggested that cytochrome P450 monooxygenases are involved in pyflubumide  
32 resistance. We therefore conducted genome-wide gene expression experiments to investigate  
33 constitutive and induced expression patterns and documented the overexpression of five cytochrome  
34 P450 and four CCE genes in JPR-Rs after pyflubumide exposure. Together, we provide a thorough  
35 resistance risk assessment of a novel complex II inhibitor, and provide first evidence for metabolic  
36 resistance mediated by cytochrome P450s in *T. urticae*.

37 **Keywords**

38 Pyflubumide, selection, Complex II, Cytochrome P450, Cross-resistance, Cyenopyrafen

39 **Key message**

40 • This study provides a thorough resistance risk assessment of the novel mitochondrial complex  
41 II inhibitor pyflubumide in *Tetranychus urticae*.

42 • We identified a low-to-moderate level of cross-resistance to pyflubumide in the cyenopyrafen  
43 resistant strain JPR.

44 • Under pyflubumide selection pressure, JPR rapidly evolved high level resistance, but only in  
45 females.

46 • Target-site insensitivity could not be detected in the resistant strains.

47 • Synergism/antagonism experiments followed by genome-wide gene expression experiments  
48 strongly suggest that cytochrome P450 monooxygenases are involved in pyflubumide  
49 resistance.

50

51 **Author Contribution**

52 SMF, NW and TVL conceived and designed research. SMF, CM conducted experiments. SMF, TVL  
53 and NW analyzed data and wrote the manuscript. All authors read and approved the manuscript.

54 **Introduction**

55 The two-spotted spider mite, *Tetranychus urticae* Koch (Arthropoda: Chelicerata: Acariformes) is an  
56 important cosmopolitan agricultural pest that causes significant yield losses in the absence of a proper  
57 pest and resistance management strategy (Jeppson et al. 1975; Van Leeuwen et al. 2015). The application  
58 of acaricides still remains the most frequently used method to keep *T. urticae* populations below  
59 economic thresholds for many crops. However, the fast development of resistance in the species, in part  
60 due to biological characteristics such as a short life cycle, high reproductive potential, arrhenotokous  
61 reproduction, together with a broad host plant range, reduces the efficacy of the application of acaricides  
62 (Dermauw et al. 2013; Van Leeuwen et al. 2010; Wybouw et al. 2019). It is therefore important to  
63 continue to develop acaricides with new modes of action and limited cross-resistance to other  
64 commercially available compounds to secure proper resistance management in *T. urticae* (Nauen et al.  
65 2012; Van Leeuwen, Thomas et al. 2015; Fotoukkiaii et al. 2019). The carboxanilide pyflubumide is a  
66 recently developed acaricide by Nihon Nohyaku Co. Ltd with excellent activity against phytophagous  
67 mites of the genus *Tetranychus* and *Panonychus* (both belong to the Tetranychidae family) (Nakano et  
68 al. 2015). Pyflubumide is structurally similar to the carboxamide fungicides that inhibit succinate-  
69 dehydrogenase. Pyflubumide, together with the beta-ketonitriles cyenopyrafen and cyflumetofen, are  
70 the first commercially developed acaricides that act as complex II inhibitors in the mitochondrial  
71 electron transport chain (Furuya et al. 2017; Van Leeuwen et al. 2015). Similar to the beta-ketonitriles,  
72 pyflubumide is a pro-acaricide that is converted to a more potent de-acylated metabolite (Nakano et al.  
73 2015). Although the metabolites of pyflubumide and cyenopyrafen are reported to both strongly inhibit  
74 complex II, different binding modes have been suggested with the target-site (Furuya et al. 2015;  
75 Nakano et al. 2015). Cross-resistance to conventional acaricides in Japanese field collected resistant  
76 populations was not detected for pyflubumide (Furuya et al. 2015). The specificity of pyflubumide and  
77 its compatibility with non-target arthropods such as pollinators and natural enemies make it an ideal  
78 candidate for integrated pest management (IPM) programs (Furuya et al. 2017; Van Leeuwen et al.  
79 2015).

80 In this study, the baseline activity and potential cross-resistance risk of pyflubumide was explored by  
81 analyzing its toxicity in a reference panel of *T. urticae* strains resistant to various acaricides with

82 different modes of action. The base line toxicity on adult females, males, and eggs of resistant and  
83 susceptible mites was also assessed. Our survey identified a strain resistant to cyenopyrafen (JPR) as  
84 the only strain with a low-to-moderate level of cross-resistance to pyflubumide. We subsequently  
85 selected JPR for higher levels of pyflubumide resistance and finally obtained two highly resistant strains.  
86 To gain further insight into the molecular mechanisms that underpin pyflubumide resistance, we  
87 screened for potential target-site resistance mutations, conducted synergism/antagonism experiments,  
88 and analyzed transcriptomic changes under various conditions between susceptible and resistant strains.  
89

## 90 **Materials and methods**

### 91 **Survey of pyflubumide resistance**

92 A reference panel of fifteen acaricide-susceptible and -resistant *T. urticae* strains (Table 1) were  
93 screened for resistance to pyflubumide in toxicity bioassays on adult female mites as described below.  
94 All strains were maintained on potted bean plants *Phaseolus vulgaris* L. cv. “Speedy” at  $25 \pm 1^\circ\text{C}$ , 60%  
95 RH, and 16:8 h (L:D) photoperiod. Commercial formulations (20% SC, Danikong) of pyflubumide was  
96 kindly provided by Ralf Nauen. All other chemicals and synergists were analytical grade and purchased  
97 from Sigma-Aldrich.

### 98 *Selection for pyflubumide resistance*

99 To assess the risk of the development of pyflubumide resistance in *T. urticae*, JPR was reared with  
100 pyflubumide selection pressure under two different laboratory regimes, as described below. The two  
101 derived strains are referred to as JPR-R1 and JPR-R2.

#### 102 1) Plate selection regime

103 Approximately 2000 adult female JPR mites were placed on four detached bean leaves in separate Petri  
104 dishes (about 500 females per leaf). Mites were sprayed with 1 ml of 100 mg/L pyflubumide (~ LC90  
105 of JPR) using a Potter spray tower resulting in 2 mg aqueous deposit per  $\text{cm}^2$ . After 48 h, females that  
106 appeared unaffected were transferred to untreated bean plants and allowed to propagate for  
107 approximately three generations. The dose-response relationship of pyflubumide toxicity was assessed  
108 in this generation, hereafter called SEL1. A second round of selection was undertaken with 1000 mg/L

109 pyflubumide using the same approach, resulting in generation SEL2. From generation SEL2 onwards,  
110 the population was grown on bean plants sprayed until run off with 100 mg/L. The resulting resistant  
111 strain was named JPR-R1.

112 2) On plant selection regime

113 Approximately 2000 adult female JPR mites were transferred to potted bean plants that were sprayed  
114 with a hand-hold spraying device with 100 mg/L pyflubumide until run-off. Before spraying, plant buds  
115 were removed and only the primary leaves were kept on the potted bean plants. After seven days, all  
116 apparent unaffected mites (from all stages and both sexes) were collected and transferred to untreated  
117 bean plants for propagation. The strain was named JPR-R2 and maintained on potted bean plants with a  
118 constant selection pressure of 100 mg/L of pyflubumide until analysis.

### 119 **Toxicity bioassays**

120 Bioassays were performed on eggs, adult females and males. To obtain eggs of a synchronized age for  
121 egg bioassays, 50-60 adult females were placed on the upper side of 9 cm<sup>2</sup> bean leaf discs and allowed  
122 to oviposit for 4 h. After removing adult mites, the number of eggs were counted per petri dish. After  
123 24 h, the eggs were sprayed with 1 mL of spray fluid at 1 bar pressure in the Potter spray tower, resulting  
124 in 2 mg aquous deposit per cm<sup>2</sup>. Four replicates of five-eight concentrations of pyflubumide and a  
125 control (deionized water) were tested. Mortality was scored after 5 days. Percentage of mortality was  
126 calculated by dividing the number of hatched larvae to the number of eggs.

127 Female and male bioassays were conducted using a standardized method previously described by (Van  
128 Leeuwen et al. 2006). Briefly, we tested five-eight concentrations in four replicates. For each replicate  
129 20-30 adults were transferred to 9 cm<sup>2</sup> bean leaf discs on wet cotton wool. Leaf discs were sprayed as  
130 outlined above, and mortality was scored after 24 h.

131 LC<sub>50</sub>-values and the 95% confidence limits were calculated from probit regressions using the POLO-  
132 Plus software (LeOra Software, 2006).

### 133 **Sequencing of SQR subunits**

134 DNA extraction of the JPR and JPR-R populations was performed as described by Van Leeuwen (2008)  
135 (Van Leeuwen et al. 2008). Briefly, approximately 200 adult females were collected and homogenized

136 in 800  $\mu$ L SDS buffer (200mM Tris-HCl, 400 mM NaCl, 10 mM EDTA, 2% SDS at pH = 8.3) followed  
137 by a phenol-chloroform extraction. The four subunits of JPR-R2 and JPR strains were sequenced using  
138 the primer pairs listed in supplemental file 1. PCR reactions were conducted in 50  $\mu$ L of reaction mixture  
139 containing 2 mM of MgCl<sub>2</sub>, 0.2  $\mu$ M of each primer, 0.2 mM of deoxynucleotide triphosphate (dNTP)  
140 mix (Invitrogen, Merelbeke, Belgium), 5  $\mu$ L of 10 $\times$  PCR-buffer (Invitrogen) and 1U of Taq DNA  
141 polymerase (Invitrogen), under the following conditions: 2 min at 95 °C, 35 cycles of 15 s at 95 °C, 30  
142 s at 55 °C and 30 s at 72 °C, and a final extension of 2 min at 72 °C. After purification using E.Z.N.A.  
143 Cycle-Pure kit (Omega Bio-tek, Norcross, GA, USA), PCR products were sequenced at LGC Genomics  
144 (Germany). All SQR subunits of JPR-R2 and JPR were screened for nucleotide variants using those of  
145 the London strain as reference.

#### 146 **Synergism/antagonism and barbital experiments**

147 Synergism/antagonism experiments were performed according to the methods described by Van  
148 Pottelberge et al. (2009). Briefly, 1,000 mg/L of piperonyl butoxide (PBO), 500 mg/L of S,S,S-tributyl  
149 phosphorotriethioate (DEF) and 2,000 mg/L of diethylmaleate (DEM) were used as the final  
150 concentrations in the experiments. The synergists/antagonists were first dissolved in N, N dimethyl  
151 formamide and emulsifier W (3:1), and then diluted to the respective concentrations  
152 using deionized water. Mites were sprayed with 1 ml of the synergist/antagonist solution as described  
153 above. Exactly 24 h after synergist treatment, mites were used in pyflubumide bioassays. Mortality was  
154 recorded after 24 h and synergism ratios (SR) were determined by dividing the LC<sub>50</sub> of pyflubumide  
155 alone by the LC<sub>50</sub> obtained after synergist pre-treatment.

156 For barbital assays, the methods described by (Van Pottelberge et al. 2008) were followed. In short, the  
157 barbital solution was made by dissolving barbital powder in deionized water. Each replicate (20-30 adult  
158 females) was sprayed with 1 ml of 10,000 mg/L barbital solution as described above. After 4 h, mites  
159 were sprayed with five-eight concentrations of pyflubumide and a control each with four replicates. The  
160 synergism/antagonism ratio was determined by dividing the LC<sub>50</sub> of treated population by the LC<sub>50</sub> of  
161 non-treated population.

#### 162 **Timing of symptomology**

163 To determine the timing of symptomology, we used 100 mg/L pyflubumide which is a concentration  
164 that did not lead to physiological symptoms in JPR-R1 and JPR-R2 strains. About 30 adult female mites  
165 from strains JPR, JPR-R1, and JPR-R2 were transferred to the upper side of 9 cm<sup>2</sup> bean leaf discs in ten  
166 replicates. All 30 petri dishes were sprayed with 100 mg/L of pyflubumide using the Potter spray tower  
167 as described above. Four replicates were sprayed with deionized water as a control. All plates were  
168 checked every 1.5 h, starting 1h into the photophase, until the18 h timepoint, with a final observation at  
169 24 h. Dead mites and mites that proved unable to walk the length of their body or displayed  
170 uncoordinated behavior (spastic movement) after a gentle touch by a tiny brush were recorded as  
171 affected. Significant differences in the percentage of affected mites across time points were determined  
172 using a General Linear Model (GLM) followed by Tukey's HSD tests ( $\alpha = 0.05$ ). Statistical analysis was  
173 conducted within the R framework [R Core Team (2014), version 3.1.2] (Team 2018).The experiment  
174 was conducted at 23-25 °C, 60% RH, and 18/6h (L/D) photoperiod with the photophase started at 6:00  
175 AM.

#### 176 **Experimental set-ups for the transcriptomic analyses of pyflubumide resistance**

177 Three transcriptomic experiments were performed that differed in the way *T. urticae* strains were  
178 exposed to pyflubumide. First, four RNA samples were collected from JPO (the ancestral strain of JPR)  
179 (Sugimoto and Osakabe 2014), JPR, JPR-R1, and JPR-R2 that were maintained for one generation on  
180 non-sprayed plants. Next, four samples were collected from JPR and JPR-R1 that were either exposed  
181 to pyflubumide or deionized water for 9 h. Here, approximately 500 adult female mites were placed on  
182 detached leaf discs on wet cotton wool and were sprayed with 1 ml of pyflubumide solution (100 mg/L)  
183 or deionized water at 1 bar pressure in a Potter spray tower resulting in 2 mg aqueous deposit per cm<sup>2</sup>.  
184 Last, four RNA samples were collected from JPR-R1 and JPR-R2 that were either sprayed with  
185 pyflubumide (100 mg/L) or deionized water 24 h before collection, using the same methodology as for  
186 the 9h time point.

#### 187 **RNA extraction and transcriptomic analyses of pyflubumide resistance**

188 Per sample, RNA was extracted from a bulk of 120-150 adult females using a RNeasy minikit (Qiagen),  
189 treated with DNase (Turbo, Ambion), and labelled using the Low Input Quick Amplification Kit

190 (Agilent Technologies). RNA samples were dyed with cyanine-3 or cyanine-5. Cyanine-labeled RNA  
191 was hybridized in the respective mixes (cyanine-5 and cyanine-3) to a custom Agilent GE microarray  
192 (Gene Expression Omnibus (GEO) Platform GPL16890). After washing using the Gene Expression  
193 Wash Buffer kit (Agilent Technologies), microarray slides were scanned with an Agilent Microarray  
194 High-Resolution Scanner. The raw intensity values are accessible at the GEO website (GSE138192) and  
195 were used for statistical analysis in limma (Smyth Gordon 2004). Background correction was performed  
196 using the ‘normexp’ method (with an offset of 50) (Ritchie et al. 2007). Within- and between-array  
197 normalization was applied using the global loess and Aquantile methods, respectively. Data quality was  
198 assessed at every step using arrayQualityMetrics (Kauffmann et al. 2008). Using the probe annotation  
199 identified in (Snoeck et al. 2018), a linear model was fitted to the processed data, incorporating intraspot  
200 correlations (Smyth and Altman 2013). Significant differential gene-expression was identified by  
201 empirical Bayesian statistics with cut-offs of Benjamini-Hochberg corrected *p*-values and log<sub>2</sub>FC at 0.05  
202 and 1, respectively. A Principal Component Analysis (PCA) was performed on relative transcription  
203 levels using the prcomp function within the R environment (Team 2018). An optimal number of clusters  
204 for *k*-means clustering was assessed using the gap statistic (global max, seed number set at 54321, cluster  
205 number ranging from 2 to 10) (Tibshirani et al. 2001). Using JPO as a common reference, the relative  
206 gene-expression levels of genes that were significantly differentially expressed in any comparison were  
207 used as input and clustered using the centered Pearson’s correlation as distance metric.

208 **Results**

209 **Pyflubumide cross-resistance screen and selection**

210 The toxicity of pyflubumide in a number of laboratory and field-collected *T. urticae* strains is shown in  
211 Table 1. All strains displayed similar LC<sub>50</sub> values (2-7 mg/ L), with the exception of JPR, that exhibited  
212 an LC<sub>50</sub> value of 49 (37.62 - 65.63) mg/ L.

213 To assess the risk of resistance development, JPR was selected for pyflubumide resistance using two  
214 different selection regimes. After selection with 100 mg/L on plates, the resulting population SEL1  
215 displayed an LC<sub>50</sub> value of 247.78 (190.58 - 303.23) mg/L. A second selection with 1,000 mg/L resulted  
216 in population SEL2 with LC<sub>50</sub> of 824.96 (693.47 to 966.43) mg/L. The population was further

217 maintained on sprayed plants with 100 mg/L and the LC<sub>50</sub> of the final population, JPR-R1, was 1,437.48  
218 (1,221.26 – 1,666.77) mg/L (Fig. 1).

219 In an alternative approach, the strain JPR was independently selected for pyflubumide resistance on  
220 potted plants, and resulted in the JPR-R2 strain, with an LC<sub>50</sub> value of 1,893.67 (1,641.63 – 2,156.25)  
221 mg/ L.

## 222 **Toxicity of pyflubumide on females, males, and eggs of susceptible and resistant mites**

223 The LC<sub>50</sub> values of pyflubumide on females, males and eggs of Wasatch, JPR, JPR-R1 and JPR-R2  
224 strains are reported in Table 2. Pyflubumide was toxic to all tested stages of Wasatch, but males were  
225 about 10-fold more susceptible, while eggs were clearly less susceptible (Table 2). While resistance  
226 levels were high in adults in both JPR-R strains, eggs showed a marked higher susceptibility (54.10 and  
227 98.19 mg/ L) to pyflubumide, and resistance levels were also lower in males. In contrast, resistance  
228 levels in parental JPR were low in adults (49 mg/L) and higher in eggs (318 mg/L), a pattern that was  
229 apparently not maintained, nor fortified by selection for pyflubumide resistance.

## 230 **Sequencing of the succinate: ubiquinone oxidoreductase subunits**

231 Only synonymous SNPs were identified in *tetur01g15710* (*SdhB*), *tetur30g00210* (*SdhC*) and  
232 *tetur20g00790* (*SdhD*). In *tetur08g03210* (*SdhA*), we found a substitution V209I between the London  
233 sequence (V209) and both JPR (I209) and JPR-R2 (I209). Coding sequences generated in this study are  
234 accessible at the NCBI repository (XXXX).

## 235 **Synergism and antagonism assays**

236 The effect of synergists PBO, DEF and DEM on pyflubumide toxicity are presented in Table 3.  
237 Synergism/antagonism assays were performed on susceptible LS-VL, JPR, JPR-R1 and JPR-R2.  
238 Pyflubumide toxicity was synergized two-fold by PBO in JPR and much higher in JPR-R1 and JPR-R2  
239 with remarkable SRs of 15- and 20-fold, respectively. DEF antagonized pyflubumide toxicity in all  
240 strains, however, the antagonism was about 10-fold higher in JPR. The synergistic effects with DEM  
241 was higher in JPR-R1 and JPR-R2 compared with JPR (Table 3). The results of phenobarbital effect on  
242 toxicity of pyflubumide are presented in Table 4. Barbital treatment decreased the toxicity of  
243 pyflubumide more in JPR-R1 and JPR-R2, as compared with JPR (Table 4).

244 **Constitutive transcriptomic changes associated with selection for pyflubumide resistance**

245 To characterize potential constitutive, or environmentally independent, transcriptomic changes  
246 associated with selection for pyflubumide resistance, the transcriptomes were sampled of JPO, JPR,  
247 JPR-R1, and JPR-R2, all maintained for one generation without selection pressure on non-sprayed bean  
248 plants. A PCA shows that the transcriptomic profile of JPO was highly divergent from JPR and JPR-  
249 R1-2 and that a low percentage of the total data variation underlined the differences between JPR and  
250 JPR-R1-2 (Fig. 2A). Using JPR as the parental reference, a small number of genes were significantly  
251 differentially transcribed in JPR-R1 and JPR-R2 (47 and 37, respectively) (Fig. 2B and Supplemental  
252 file 2). Of these, only 14 genes were consistently differentially expressed in both JPR-R1 and JPR-R2.  
253 Three genes (*tetur13g01730*, *tetur14g03160*, and *tetur14g01700*) were consistently up-regulated upon  
254 pyflubumide selection, but none coded for enzymes that are known to be associated with xenobiotic  
255 metabolism (hypothetical proteins and a protein with an ‘Immunoglobulin E-set’ domain (IPR014756),  
256 respectively) (Fig. 2B and Supplemental file 2). One of the genes with a lower transcription level in  
257 JPR-R1 and JPR-R2, *tetur03g00830*, coded for the cytochrome P450 CYP392A12 (Fig. 2B). No  
258 carboxyl/cholinesterase (CCE) genes were down-regulated in these two comparisons. We hypothesized  
259 that the transcriptomic signature of pyflubumide resistance might have been masked in these  
260 comparisons because it was already present in the ancestral, cross-resistant JPR strain. Therefore, as a  
261 next step, we used the original and susceptible JPO strain (the parent of JPR) as a reference to look at  
262 transcriptomic changes. Compared to JPO, 454 genes were differentially expressed in JPR, whereas 362  
263 and 368 differentially expressed genes (DEGs) were detected in JPR-R1 and JPR-R2, respectively  
264 (Supplemental Tables). Selecting JPR from JPO was associated with the up-regulation of 16 cytochrome  
265 P450 genes, with *CYP392D2*, *CYP392D6*, and *CYP392A12* having a  $\log_2FC$  higher than four. Two CCE  
266 genes (*tetur17g00360* and *tetur30g01290*) were down-regulated in JPR compared to JPO, whereas six  
267 CCE genes showed a significant up-regulation. In both JPR-R1 and JPR-R2, 13 cytochrome P450s were  
268 up-regulated compared to JPO, of which 11 genes already showed significant up-regulation in JPR  
269 (*CYP392D2*, *CYP392D6*, and *CYP392E8* had the highest average transcriptional increase  
270 (Supplementary Tables)). JPR-R1 and JPR-R2 each had one unique up-regulated cytochrome P450  
271 (*tetur03g05040* and *tetur06g02620*, respectively (both are not full-length in the reference London

272 genome (Grbić et al. 2011))). *Tetur03g05010* was the only cytochrome P450 (*CYP392D4*) that was up-  
273 regulated in JPR-R1-2, but not in JPR (average  $\log_2$ FC of 1.02). Only JPR-R1 had a down-regulated  
274 CCE gene that was not already down-regulated in JPR; *tetur01g10800* with a  $\log_2$ FC of -1.08. To gain  
275 more insight into the transcriptional evolution of these and other genes, all 560 DEGs were grouped  
276 using *k*-means clustering, and three distinct transcriptional patterns became apparent (Fig. 2C and  
277 Supplemental Tables). The 513 DEGs of cluster 1 and 2 showed a stable down- and up-regulation,  
278 respectively, across JPR, JPR-R1, and JPR-R2. The 47 DEGs of cluster 3 showed a high relative  
279 transcription level in JPR-R1-2, but not in JPR. Notably, *CYP392D4* was placed in this group of DEGs.

## 280 **Symptomology timing**

281 In order to gain insights in the time of toxicity in relation to potential plastic transcriptional changes,  
282 mites were exposed to pyflubumide and cumulative percentages of mortality and symptoms were  
283 followed during 24 h after spraying with a sub-lethal dose of pyflubumide in JPR and JPR-R1-2 (Fig.  
284 3). The highest level of pyflubumide-induced toxicity symptoms was observed nine hours after spraying  
285 in both JPR-R1 ( $df = 2$ ;  $F = 7.90$ ;  $P = 0.0019$ ) and JPR-R2 ( $df = 2$ ;  $F = 12.63$ ;  $P < 0.0001$ ). The symptom  
286 level at this time point was significantly different from that of the previous time points, i.e., 7.5 h  
287 (Tukey's post hoc test,  $P < 0.001$  for both JPR-R1 and JPR-R2) and the next time point at 10.5 h  
288 (Tukey's post hoc test,  $P = 0.038$  and  $P = 0.037$  for JPR-R1 and JPR-R2, respectively). After 9 h the  
289 symptoms declined in JPR-R1-2, whereas JPR showed an increase in the level of symptoms (Fig. 3).

## 290 **Plastic transcriptomic responses to pyflubumide exposure**

291 As only limited constitutive gene expression differences were observed between JPR and JPR-R1-2, the  
292 plastic, environmentally dependent, transcriptomic changes were also characterized to shed more light  
293 on the molecular basis of pyflubumide resistance. Based on the symptomology bioassays, we first  
294 investigated the transcriptomic responses of JPR and JPR-R1 after nine hours of exposure to a sub-lethal  
295 dose of pyflubumide (100 mg/L). Here, no DEGs were detected in JPR-R1 upon pyflubumide exposure,  
296 whereas a single DEG (*tetur04g04350*,  $\log_2$ FC of 1.17) was observed in JPR. Next, we focused on the  
297 plastic responses of JPR-R1-2 upon 24 h of exposure to the same sub-lethal dose of pyflubumide, versus  
298 water-sprayed controls. As reflected in the PCA (alongside the PC1 axis, Fig. 4A), large transcriptomic

299 changes were observed here, clearly separating water-sprayed from pyflubumide-sprayed populations.  
300 Using water-sprayed populations as respective references, JPR-R1 had 294 DEGs, whereas JPR-R2  
301 exhibited 118 DEGs (Fig. 4B). Over 92% of the transcriptional response of JPR-R2 was also present in  
302 the response of JPR-R1, and the shared DEGs (n=109) exhibited a positive relationship in their plastic  
303 transcriptional response (Fig. 4B). Eight cytochrome P450s were part of this positively correlated  
304 response, of which five showed up-regulation after exposure to pyflubumide (Fig. 4B). Four CCE genes  
305 were up-regulated when the resistant strains were exposed to pyflubumide (Supplementary Tables).

## 306 **Discussion**

307 The development of new acaricides with new modes of action and limited cross-resistance to other  
308 conventional compounds remains crucial for efficient resistance management of phytophagous mite  
309 pests like *T. urticae* (Nauen et al. 2012). Pyflubumide is a newly developed complex II inhibitor and the  
310 first acaricide with a carboxanilide structure (Furuya et al. 2017). In this study, the compound proved to  
311 be very active on a collection of strains with varying levels of resistance to commercially available  
312 compounds. However, we uncovered decreased susceptibility in a Japanese strain named JPR, which  
313 was selected out of JPO with cyenopyrafen (Sugimoto and Osakabe 2014). The decreased pyflubumide  
314 susceptibility was only found in JPR, and not its parent JPO, suggesting that selection for cyenopyrafen  
315 resistance resulted in decreased susceptibility for pyflubumide (Table 1), a typical case of moderate  
316 cross-resistance. As cyenopyrafen and pyflubumide both belong to complex II inhibitors acaricides and  
317 their active metabolites act on the same enzyme (Nakano et al. 2015), cross-resistance is not surprising,  
318 although pyflubumide and cyenopyrafen belong to different chemical families, and might have slight  
319 different binding modes (Nakano et al. 2015). In addition, cross-resistance between cyenopyrafen and  
320 cyflumetofen, both beta-ketonitriles, has been demonstrated in JPR (Khalighi et al. 2016).

321 Before studying the mechanisms of (cross)-resistance, we attempted to further fix pyflubumide  
322 resistance in JPR using two different laboratory selection regimes, and obtained two highly resistant  
323 strains, JPR-R1 and JPR-R2. Pyflubumide resistance evolved very quickly (Fig. 1), indicating that under  
324 field conditions pyflubumide efficacy would be at risk after prior selection with cyenopyrafen.

325 In the susceptible Wasatch strain, males were much more susceptible to pyflubumide than females, while  
326 in contrast, eggs were much less susceptible. Variation in pesticide susceptibility between sexes and  
327 developmental stages of pest species can be related to morphological differences (e.g. body size or egg  
328 shell thickness) and/or metabolic differences (e.g. differential expression of detoxifying enzymes). A  
329 smaller male and egg size in *T. urticae* can provide a higher exposure to acaricides through higher  
330 surface-to-volume ratios, although sexual size dimorphism is not always related to variation in pesticide  
331 tolerance (Daly and Fitt 1990; Rathman et al. 1992). When assessing stage-specific effects of  
332 pyflubumide resistance, we discovered that unlike adult females, males and eggs of the two JPR-R  
333 strains were still highly susceptible to pyflubumide, so resistance was strongly female biased. This  
334 pattern was however not observed for JPR where eggs retained most of the resistance levels (Table 2).  
335 As resistance levels were maintained in eggs versus adults in JPR, but not in JPR-R, this would suggest  
336 that at least additional mechanisms were selected. Stage specific effects in resistance has been previously  
337 reported in spider mites; spirodiclofen resistance is high in adult *T. urticae* females but absent in eggs  
338 (Van Pottelberge, Van Leeuwen, Khajehali et al. 2009). Sex-linked pesticide resistance has been  
339 observed in haplodiploid species such as spider mites where unfertilized haploid eggs develop into males  
340 and fertilization leads to diploid females (Carrière 2003). One of the underlying mechanisms might be  
341 a dosage-effect of the resistance alleles in haploid males (Carrière 2003). This mechanism is similar to  
342 sex-linked pesticide resistance in diplodiploid species in which the sex-linked allele is not always  
343 present, or expressed in a specific gender (Baker et al. 1994; Marín et al. 2000; Rao and Padmaja 1992).  
344 Of practical importance, the effectiveness of resistance management strategies is higher when such sex-  
345 linked pesticide resistance patterns are taken into account as the susceptibility of males (and  
346 developmental stages such as eggs) might slow down the resistance development process by reducing  
347 the overall population growth.

348 Pyflubumide is structurally similar to the carboxamide fungicides that act as a complex II inhibitors  
349 (SDHI), and a similar mode of action has been documented (Furuya et al. 2017). Resistance to SDHI  
350 fungicides has been reported to be conferred by specific point mutations in complex II subunits (SDHB,  
351 -C, and -D) in many fungal plant pathogens (Avenot and Michailides 2010; Oliver 2014; Sierotzki and

352 Scalliet 2013). Because of the apparently frequent target-site resistance development in fungi, and the  
353 observed cross-resistance between pyflubumide, cyenopyrafen and cyflumetofen (all acting on complex  
354 II), we first searched for target-site resistance by sequencing all subunits (SDHA, until -D) that make up  
355 complex II. However, we did not find any target-site resistance mutation in subunits SDHB, SDHC and  
356 SDHD, previously implicated in QoI resistance in fungi (Avenot and Michailides 2010; Hahn 2014;  
357 Sierotzki and Scalliet 2013). The V209I variant in SDHA in JPR and JPR-R2 was not positioned in a  
358 conserved region and very likely not associated with resistance, as the ubiquinone-binding pocket where  
359 pyflubumide interacts is structurally defined by the interface between the SDHB, -C, and -D subunits  
360 (Sierotzki and Scalliet 2013), and is likely the reason why mutations in SDHA have not been uncovered  
361 in fungi yet. This is in line with a previous study that did not find target-site resistance in the  
362 cyenopyrafen resistant strain JPR (Khalighi et al. 2016) and points toward an alternative mechanism of  
363 (cross)-resistance.

364 Synergism experiments strongly suggested that cytochrome P450 monooxygenases and glutathione S-  
365 transferases are involved in pyflubumide detoxification in female resistant mites in the two JPR-R strains  
366 (Table 3). To a lesser extent, this is also true for JPR (2-fold PBO synergism). A strong antagonism of  
367 toxicity was found after treatment with DEF, which confirms pyflubumide is a pro-acaricide that  
368 requires hydrolytic activation (Khajehali et al. 2009; Nakano et al. 2015; Van Leeuwen et al. 2006).  
369 Interestingly, antagonism is much higher in JPR compared to both the susceptible LS-VL and resistant  
370 JPR-R strains, again pointing towards different mechanisms between parental and selected strains.  
371 Pretreatment with barbital dramatically lowered the resistance levels of JPR-R1-2 and JPR, whereas it  
372 slightly increased pyflubumide resistance in the susceptible strain LS-VL. This suggests that the  
373 detoxifying enzymes, most likely cytochrome P450s, were more suppressed than induced by barbital in  
374 the resistant strains. Collectively, it seems likely that the differences in pyflubumide susceptibility of  
375 eggs and males of the resistant strains might be due to a different detoxification potential. Higher levels  
376 of resistance in the JPR-R strains correlate with higher synergism ratio for PBO and DEM.  
377 Therefore, we performed a genome wide gene-expression analysis between parental (JPR) and selected  
378 resistant lines JPR-R. Transcriptome analysis did not show any notable differences between strains in

379 the absence of acaricide pressure (Fig. 2A-B). In contrast, when JPO was used as the reference, over  
380 500 genes were differentially transcribed in JPR and JPR-R1-2 with the majority of the DEGs exhibiting  
381 stable transcript levels (Fig. 2C). Cluster analysis revealed a small group of DEGs that show an increased  
382 expression in JPR-R1-2, compared to JPO (Fig. 2C, cluster 3). The cytochrome P450 CYP392D4 is  
383 clustered in this group, and it belongs to the CYP392 family that underwent a spider mite-specific  
384 expansion (Grbić et al. 2011) and of which many members have been implicated in resistance in *T.*  
385 *urticae* (Demaeght et al. 2013a; Riga, M. et al. 2014; Van Leeuwen and Dermauw 2016). Together,  
386 these results suggest that the constitutive transcriptomic signature of pyflubumide resistance was already  
387 present in JPR and did not significantly change when selecting for higher resistance levels in JPR-R1-2  
388 (Fig. 2A). We therefore tested the hypothesis whether the high pyflubumide resistance of JPR-R1-2  
389 could be caused by a heritable increased plasticity (induction by pyflubumide). In our observations of  
390 the symptomology timing, the highest level of JPR-R responses to pyflubumide was observed 9 h after  
391 exposure to the acaricide. Afterwards, the symptoms declined, which suggests that the detoxifying  
392 mechanisms were activated after this time. We indeed found that five cytochrome P450s and four CCE  
393 genes were up-regulated when JPP-R1-2 were exposed to pyflubumide for 24 h, compared to water-  
394 sprayed JPR-R1-2 mites. Here, the up-regulation of cytochrome P450s further supports our hypothesis  
395 that pyflubumide resistance is metabolic.

396 Together, our results show that although many resistant *T. urticae* strains were susceptible to  
397 pyflubumide, there could be a risk of rapid development of pyflubumide resistance in the areas that have  
398 been exposed to cyenopyrafen and probably other complex II inhibitors. We gathered evidence that  
399 indicates that cytochrome P450 enzymes are likely involved in pyflubumide resistance. However, gene-  
400 expression patterns have shown to be complex and failed to clearly identify which cytochrome P450(s)  
401 might be involved. Future work should focus on trying to get functional data on pyflubumide  
402 metabolizing enzymes and characterize resistance with alternative hypothesis-free approaches such as  
403 QTL mapping (Kurlovs et al. 2019).

404 **Acknowledgments**

405 This work was partially funded by the University of Amsterdam (IBED), and it was supported by the  
406 Research Foundation - Flanders (FWO) [grant G009312N and grant G053815N] and the Research  
407 Council (ERC) under the European Union's Horizon 2020 research and innovation program [grant  
408 772026-POLYADAPT and 773902–SUPERPEST]. N.W. was supported by a Research Foundation -  
409 Flanders (FWO) post-doctoral fellowship (12T9818N).

410 **References**

411 Asahara M, Uesugi R, Osakabe M (2008) Linkage between one of the polygenic hexythiazox resistance  
412 genes and an etoxazole resistance gene in the two spotted spider mite (Acari: Tetranychidae). *J Econ*  
413 *Entomol* 101:1704-1710

414 Avenot HF, Michailides TJ (2010) Progress in understanding molecular mechanisms and evolution of  
415 resistance to succinate dehydrogenase inhibiting (SDHI) fungicides in phytopathogenic fungi 29:643-  
416 651

417 Baker BS, Gorman M, Marin I (1994) Dosage compensation in *Drosophila*. *Annu Rev Genet* 28:491-  
418 521

419 Carrière Y (2003) Haplodiploidy, sex, and the evolution of pesticide resistance. *J Econ Entomol*  
420 96:1626-1640

421 Daly JG, Fitt GP (1990) Monitoring for pyrethroid resistance in relation to body weight in adult  
422 *Helicoverpa armigera* (Hübner) (Lepidoptera: Noctuidae). *J Econ Entomol* 83:705-709

423 Demaeght P, Dermauw W, Tsakireli D, Khajehali J, Nauen R, Tirry L, Vontas J, Lümmen P, Van  
424 Leeuwen T (2013a) Molecular analysis of resistance to acaricidal spirocyclic tetrone acids in  
425 *Tetranychus urticae*: CYP392E10 metabolizes spirodiclofen, but not its corresponding enol. *Insect*  
426 *Biochem Mol Biol* 43:544-554

427 Demaeght P, Dermauw W, Tsakireli D, Khajehali J, Nauen R, Tirry L, Vontas J, Lümmen P, Van  
428 Leeuwen T (2013b) Molecular analysis of resistance to acaricidal spirocyclic tetrone acids in  
429 *Tetranychus urticae*: CYP392E10 metabolizes spirodiclofen, but not its corresponding enol. *Insect*  
430 *Biochem Mol Biol* 43:544-554

431 Dermauw W, Wybouw N, Rombauts S, Menten B, Vontas J, Grbic M, Clark RM, Feyereisen R, Van  
432 Leeuwen T (2013) A link between host plant adaptation and pesticide resistance in the polyphagous  
433 spider mite *Tetranychus urticae*. *Proc Natl Acad Sci U S A* 110:E113-22

434 Fotoukkiaii SM, Tan Z, Xue W, Wybouw N, Van Leeuwen T (2019) Identification and characterization  
435 of new mutations in mitochondrial cytochrome b that confer resistance to bifenazate and acequinocyl in  
436 the spider mite *Tetranychus urticae*. *Pest Manag Sci* <https://doi.org/10.1002/ps.5628>

437 Furuya T, Machiya K, Fujioka S, Nakano M, Inagaki K (2017) Development of a novel acaricide,  
438 pyflubumide. *J PESTIC SCI* 42:132-136

439 Furuya T, Suwa A, Nakano M, Fujioka S, Yasokawa N, Machiya K (2015) Synthesis and biological  
440 activity of a novel acaricide, pyflubumide. *J PESTIC SCI* D14-087

441 Grbić M, Van Leeuwen T, Clark RM, Rombauts S, Rouzé P, Grbić V, Osborne EJ, Dermauw W, Ngoc  
442 PCT, Ortego F (2011) The genome of *Tetranychus urticae* reveals herbivorous pest adaptations. *Nature*  
443 479:487

444 Hahn M (2014) The rising threat of fungicide resistance in plant pathogenic fungi: Botrytis as a case  
445 study 7:133-141

446 Jeppson L, Keifer H, Baker E (1975) Mites injurious to economic plants. (University of California Press:  
447 Los Angeles)

448 Kauffmann A, Gentleman R, Huber W (2008) arrayQualityMetrics—a bioconductor package for quality  
449 assessment of microarray data. *Bioinformatics* 25:415-416

450 Khajehali J, Van Nieuwenhuyse P, Demaeght P, Tirry L, Van Leeuwen T (2011) Acaricide resistance  
451 and resistance mechanisms in *Tetranychus urticae* populations from rose greenhouses in the  
452 Netherlands. *Pest Manag Sci* 67:1424-1433

453 Khajehali J, Van Leeuwen T, Tirry L (2009) Susceptibility of an organophosphate resistant strain of the  
454 two-spotted spider mite (*Tetranychus urticae*) to mixtures of bifenazate with organophosphate and  
455 carbamate insecticides 49:185-192

456 Khalighi M, Dermauw W, Wybouw N, Bajda S, Osakabe M, Tirry L, Van Leeuwen T (2016) Molecular  
457 analysis of cyenopyrafen resistance in the two-spotted spider mite *Tetranychus urticae*. *Pest Manag Sci*  
458 72:103-112

459 Khalighi M, Tirry L, Van Leeuwen T (2014) Cross-resistance risk of the novel complex II inhibitors  
460 cyenopyrafen and cyflumetofen in resistant strains of the two-spotted spider mite *Tetranychus urticae*.  
461 *Pest Manag Sci* 70:365-368

462 Kurlovs AH, Snoeck S, Kosterlitz O, Van Leeuwen T, Clark RM (2019) Trait mapping in diverse  
463 arthropods by bulked segregant analysis

464 Marín I, Siegal ML, Baker BS (2000) The evolution of dosage-compensation mechanisms. *Bioessays*  
465 22:1106-1114

466 Nakano M, Yasokawa N, Suwa A, Fujioka S, Furuya T, Sakata K (2015) Mode of action of novel  
467 acaricide pyflubumide: Effects on the mitochondrial respiratory chain. *J PESTIC SCI* 40:19-24

468 Nauen R, Elbert A, McCaffery A, Slater R, Sparks TC (2012) IRAC: insecticide resistance, and mode  
469 of action classification of insecticides 1:935-955

470 Oliver RP (2014) A reassessment of the risk of rust fungi developing resistance to fungicides. *Pest  
471 Manag Sci* 70:1641-1645

472 Rao S, Padmaja M (1992) Mammalian-type dosage compensation mechanism in an insect—*Gryllotalpa*  
473 *fossor* (Scudder)—Orthoptera. *J Biosci* 17:253-273

474 Rathman R, Johnson M, Rosenheim J, Tabashnik B, Purcell M (1992) Sexual differences in insecticide  
475 susceptibility and synergism with piperonyl butoxide in the leafminer parasitoid *Diglypus begini*  
476 (Hymenoptera: Eulophidae). *J Econ Entomol* 85:15-20

477 Riga M, Tsakireli D, Ilias A, Morou E, Myridakis A, Stephanou E, Nauen R, Dermauw W, Van Leeuwen  
478 T, Paine M (2014) Abamectin is metabolized by CYP392A16, a cytochrome P450 associated with high  
479 levels of acaricide resistance in *Tetranychus urticae*. Insect Biochem Mol Biol 46:43-53

480 Riga M, Bajda S, Themistokleous C, Papadaki S, Palzewicz M, Dermauw W, Vontas J, Van Leeuwen  
481 T (2017) The relative contribution of target-site mutations in complex acaricide resistant phenotypes as  
482 assessed by marker assisted backcrossing in *Tetranychus urticae*. Scientific reports 7:9202

483 Ritchie ME, Silver J, Oshlack A, Holmes M, Diyagama D, Holloway A, Smyth GK (2007) A  
484 comparison of background correction methods for two-colour microarrays. Bioinformatics 23:2700-  
485 2707

486 Sierotzki H, Scalliet G (2013) A review of current knowledge of resistance aspects for the next-  
487 generation succinate dehydrogenase inhibitor fungicides. Phytopathology 103:880-887

488 Smyth Gordon K (2004) Linear Models and Empirical Bayes Methods for Assessing Differential  
489 Expression in Microarray Experiments 3:1

490 Smyth GK, Altman NS (2013) Separate-channel analysis of two-channel microarrays: recovering inter-  
491 spot information. BMC Bioinformatics 14:165

492 Snoeck S, Wybouw N, Van Leeuwen T, Dermauw W (2018) Transcriptomic Plasticity in the Arthropod  
493 Generalist *Tetranychus urticae* Upon Long-Term Acclimation to Different Host Plants. G3 (Bethesda)  
494 8:3865-3879

495 Stumpf N, Nauen R (2001) Cross-resistance, inheritance, and biochemistry of mitochondrial electron  
496 transport inhibitor-acaricide resistance in *Tetranychus urticae* (Acari: Tetranychidae). J Econ Entomol  
497 94:1577-1583

498 Sugimoto N, Osakabe M (2014) Cross-resistance between cyenopyrafen and pyridaben in the  
499 twospotted spider mite *Tetranychus urticae* (Acari: Tetranychidae). Pest Manag Sci 70:1090-1096

500 Team RC (2018) R Foundation for Statistical Computing; Vienna, Austria: 2014:2013

501 Tibshirani R, Walther G, Hastie T (2001) Estimating the number of clusters in a data set via the gap  
502 statistic 63:411-423

503 Van Leeuwen T, Vanholme B, Van Pottelberge S, Van Nieuwenhuyse P, Nauen R, Tirry L, Denholm I  
504 (2008) Mitochondrial heteroplasmy and the evolution of insecticide resistance: non-Mendelian  
505 inheritance in action. Proc Natl Acad Sci U S A 105:5980-5985

506 Van Leeuwen T, Dermauw W (2016) The molecular evolution of xenobiotic metabolism and resistance  
507 in chelicerate mites. Annu Rev Entomol 61:475-498

508 Van Leeuwen T, Tirry L, Yamamoto A, Nauen R, Dermauw W (2015) The economic importance of  
509 acaricides in the control of phytophagous mites and an update on recent acaricide mode of action  
510 research. Pestic Biochem Physiol 121:12-21

511 Van Leeuwen T, Vontas J, Tsagkarakou A, Dermauw W, Tirry L (2010) Acaricide resistance  
512 mechanisms in the two-spotted spider mite *Tetranychus urticae* and other important Acari: a review.  
513 Insect Biochem Mol Biol 40:563-572

514 Van Leeuwen T, Tirry L, Nauen R (2006) Complete maternal inheritance of bifenazate resistance in  
515 *Tetranychus urticae* Koch (Acari: Tetranychidae) and its implications in mode of action considerations.  
516 Insect Biochem Mol Biol 36:869-877

517 Van Leeuwen T, Van Pottelberge S, Tirry L (2005) Comparative acaricide susceptibility and detoxifying  
518 enzyme activities in field-collected resistant and susceptible strains of *Tetranychus urticae* 61:499-507

519 Van Leeuwen T, Demaeght P, Osborne EJ, Dermauw W, Gohlke S, Nauen R, Grbic M, Tirry L,  
520 Merzendorfer H, Clark RM (2012) Population bulk segregant mapping uncovers resistance mutations  
521 and the mode of action of a chitin synthesis inhibitor in arthropods. Proc Natl Acad Sci U S A 109:4407-  
522 4412

523 Van Nieuwenhuyse P, Van Leeuwen T, Khajehali J, Vanholme B, Tirry L (2009) Mutations in the  
524 mitochondrial cytochrome b of *Tetranychus urticae* Koch (Acari: Tetranychidae) confer cross-  
525 resistance between bifenazate and acequinocyl Pest Manag Sci 65:404-412

526 Van Pottelberge S, Van Leeuwen T, Khajehali J, Tirry L (2009) Genetic and biochemical analysis of a  
527 laboratory-selected spirodiclofen-resistant strain of *Tetranychus urticae* Koch (Acari: Tetranychidae)  
528 Pest Manag Sci 65:358-366

529 Van Pottelberge S, Van Leeuwen T, Nauen R, Tirry L (2009) Resistance mechanisms to mitochondrial  
530 electron transport inhibitors in a field-collected strain of *Tetranychus urticae* Koch (Acari:  
531 Tetranychidae). Bull Entomol Res 99:23-31

532 Van Pottelberge S, Van Leeuwen T, Van Amermaet K, Tirry L (2008) Induction of cytochrome P450  
533 monooxygenase activity in the two-spotted spider mite *Tetranychus urticae* and its influence on  
534 acaricide toxicity. Pestic Biochem Physiol 91:128-133

535 Wybouw N, Kosterlitz O, Kurlovs AH, Bajda S, Greenhalgh R, Snoeck S, Bui H, Bryon A, Dermauw  
536 W, Van Leeuwen T, Clark RM (2019) Long-Term Population Studies Uncover the Genome Structure  
537 and Genetic Basis of Xenobiotic and Host Plant Adaptation in the Herbivore *Tetranychus urticae*.  
538 Genetics 211:1409-1427

539

540 **Tables**541 **Table 1** The toxicity of pyflubumide (LC<sub>50</sub> and slope) in a acaricide resistance reference panel of *T.*542 *urticae*

| Strain  | Resistant to  | Reference  | LC <sub>50</sub> (mg/L) (95% CI) <sup>a</sup> | RR*   |
|---------|---------------|--|---|-------|
| LONDON  | Susceptible   | (Khajehali et al. 2011)                              | 2.55 (2.46 - 2.63)                            | 1     |
| WASATCH | Susceptible   | (Riga et al. 2017)                                   | 3.08 (2.76 - 3.36)                            | 1.21  |
| JPO     | Unknown       | (Sugimoto and Osakabe 2014, Khalighi et al. 2016)    | 3.09 (2.87 - 3.28)                            | 1.21  |
| JPS     | unknown       | (Asahara et al. 2008, Khalighi et al. 2016)          | 5.08 (4.88 - 5.28)                            | 1.99  |
| LS-VL   | Susceptible   | (Van Leeuwen et al. 2005)                            | 3.27 (3.04 - 3.43)                            | 1.28  |
| BR-VL   | Bifenazate    | (Van Leeuwen et al. 2008)                            | 1.83 (1.63 - 2.02)                            | 0.72  |
| ETOXR   | Etoxazole     | (Van Leeuwen et al. 2012)                            | 2.70 (2.52 - 2.86)                            | 1.06  |
| TU008R  | Cyflumetofen  | (Khalighi et al. 2014)                               | 3.18 (2.95 - 3.40)                            | 1.25  |
| AKITA   | METIs         | (Stumpf and Nauen 2001)                              | 4.20 (3.95 - 4.42)                            | 1.65  |
| SR-VP   | Spirodiclofen | (Demaeght et al. 2013b; Van Pottelberge et al. 2009) | 4.30 (4.12 - 4.48)                            | 1.69  |
| MAR-AB  | Multi         | (Dermauw et al. 2013)                                | 5.86 (5.31 - 6.35)                            | 2.30  |
| HOL3    | Bifenazate    | (Van Nieuwenhuyse et al. 2009)                       | 6.01 (5.58 - 6.43)                            | 2.36  |
| MR-VL   | Multi         | (Van Leeuwen et al. 2005)                            | 6.39 (5.80 - 6.85)                            | 2.51  |
| MR-VP   | Multi         | (Dermauw et al. 2013; Van Pottelberge et al. 2009)   | 7.59 (6.80 - 8.24)                            | 2.98  |
| JPR     | Cyenopyrafen  | (Khalighi et al. 2016)                               | 49.07 (37.62 - 65.63)                         | 19.24 |

\*Resistance ratio, LC<sub>50</sub> of resistant strain/LC<sub>50</sub> of susceptible strain<sup>a</sup>The lethal concentration required to kill 50% of the population

543

544 **Table 2** The toxicity of pyflubumide (LC<sub>50</sub> and slope) in different life stages of susceptible and  
 545 resistance *T. urticae* mites

|        |                           | WASATCH         | JP-R              | JP-RR1              | JP-RR2              |
|--------|---------------------------|-----------------|-------------------|---------------------|---------------------|
|        | LC50 (mg/ L) <sup>a</sup> | 3.08            | 49.07             | 1437.48             | 1893.67             |
| Female | (95% CI) <sup>b</sup>     | (2.76 - 3.36)   | (37.62 - 65.63)   | (1221.26 - 1666.77) | (1641.63 - 2156.25) |
|        | Slope ± SE <sup>c</sup>   | 8.69 ± 0.86     | 2.15 ± 0.21       | 2.08 ± 0.20         | 2.20 ± 0.21         |
|        | RR*                       | -               | 15.93             | 466.71              | 614.83              |
|        | LC50 (mg/ L) <sup>a</sup> | 0.44            | 2.98              | 8.13                | 5.72                |
| Male   | (95% CI) <sup>b</sup>     | (0.40 ± 0.48)   | (2.73 ± 3.19)     | (7.41 ± 8.79)       | (4.97 ± 6.34)       |
|        | Slope ± SE <sup>c</sup>   | 4.83 ± 0.5      | 5.03 ± 0.42       | 4.55± 0.41          | 3.59 ± 0.42         |
|        | RR*                       | -               | 6.77              | 18.48               | 13                  |
|        | LC50 (mg/ L) <sup>a</sup> | 23.6            | 318.20            | 98.19               | 54.10               |
| Egg    | (95% CI) <sup>b</sup>     | (19.93 ± 27.60) | (258.37 ± 381.99) | (78.71 ± 118.97)    | (40.07 ± 68.91)     |
|        | Slope ± SE <sup>c</sup>   | 2.03 ± 0.14     | 1.60 ± 0.15       | 1.61 ± 0.12         | 1.42 ± 0.11         |
|        | RR*                       | -               | 13.48             | 4.16                | 2.29                |

<sup>a</sup>The lethal concentration required to kill 50% of the population

<sup>b</sup>Confidence interval to 95% of the LC estimates

<sup>c</sup>Standard error

\*Resistance ratio, LC<sub>50</sub> of resistant strain/LC<sub>50</sub> of susceptible strain

547 **Table 3** The effect of synergist/ antagonist PBO, DEF, DEM and barbital on pyflubumide toxicity in  
 548 susceptible and resistant strains of *T. urticae*

|                 |                                       | LS-VL            | JP-R                | JP-RR1              | JP-RR2              |
|-----------------|---------------------------------------|------------------|---------------------|---------------------|---------------------|
| Acaricide alone | LC <sub>50</sub> (mg/ L) <sup>a</sup> | 3.27             | 49.07               | 1437.48             | 1893.67             |
|                 | (95%CI) <sup>b</sup>                  | (3.10 - 3.41)    | (37.62 - 65.63)     | (1221.26 - 1666.77) | (1641.63 - 2156.25) |
|                 | Slope $\pm$ SE <sup>c</sup>           | 11.11 $\pm$ 0.92 | 2.15 $\pm$ 0.21     | 2.08 $\pm$ 0.20     | 2.20 $\pm$ 0.21     |
| PBO             | LC <sub>50</sub> (mg/ L) <sup>a</sup> | 2.74             | 22.82               | 92.79               | 69.21               |
|                 | (95%CI) <sup>b</sup>                  | (2.59 - 2.85)    | (19.31 - 26.71)     | (81.01 - 104.85)    | (55.66 - 84.41)     |
|                 | Slope $\pm$ SE <sup>c</sup>           | 10.40 $\pm$ 1.10 | 1.99 $\pm$ 0.17     | 2.62 $\pm$ 0.19     | 1.69 $\pm$ 0.14     |
|                 | SR <sup>d</sup>                       | 1.2              | 2.15                | 15.49               | 20.4                |
| DEF             | LC <sub>50</sub> (mg/ L) <sup>a</sup> | 7.38             | 2176.16             | 3843.95             | 5028.17             |
|                 | (95%CI) <sup>b</sup>                  | (6.86 - 7.79)    | (1834.28 - 2498.45) | (3285.81 - 4524.38) | (4245.05 - 6011.25) |
|                 | Slope $\pm$ SE <sup>c</sup>           | 7.55 $\pm$ 0.86  | 2.23 $\pm$ 0.22     | 2.08 $\pm$ 0.24     | 1.89 $\pm$ 0.24     |
|                 | SR <sup>d</sup>                       | 0.44             | 0.02                | 0.37                | 0.38                |
| DEM             | LC <sub>50</sub> (mg/ L) <sup>a</sup> | 2.36             | 21.90               | 152.30              | 73.73               |
|                 | (95%CI) <sup>b</sup>                  | (2.26 - 2.46)    | (16.00 - 28.92)     | (130.05 - 176.97)   | (58.33 - 91.05)     |
|                 | Slope $\pm$ SE <sup>c</sup>           | 6.95 $\pm$ 0.58  | 1.08 $\pm$ 0.15     | 1.59 $\pm$ 0.11     | 1.56 $\pm$ 0.10     |
|                 | SR <sup>d</sup>                       | 1.38             | 2.24                | 9.44                | 25.68               |
| Barbital        | LC <sub>50</sub> (mg/ L) <sup>a</sup> | 5.50             | 8.93                | 17.56               | 32.61               |
|                 | (95%CI) <sup>b</sup>                  | (4.90 - 5.99)    | (6.88 - 11.26)      | (14.39 - 20.94)     | (27.98 - 37.56)     |
|                 | Slope $\pm$ SE <sup>c</sup>           | 4.54 $\pm$ 0.57  | 1.77 $\pm$ 0.15     | 2.14 $\pm$ 0.18     | 2.31 $\pm$ 0.17     |
|                 | BAR Ratio <sup>f</sup>                | 1.68             | 0.18                | 0.01                | 0.02                |

<sup>a</sup>The lethal concentration required to kill 50% of the population

<sup>b</sup>Confidence interval to 95% of the LC estimates

<sup>c</sup>Standard error

<sup>d</sup>Synergism ratio, LC<sub>50</sub> of acaricide alone/LC<sub>50</sub> obtained after synergist pretreatment

<sup>f</sup>Barbital ratio, LC<sub>50</sub> of induced population/LC<sub>50</sub> of non-induced population

550 **Fig. Legends**

551 **Fig. 1 Dose-response relationships of pyflubumide toxicity on JPO, and the pyflubumide selected**  
552 **strains.** JPO is susceptible to complex II acaricides, and was first used in selection experiments. JPO  
553 was selected with cyenopyrafen resulting in JPR (Khalighi et al. 2016) and developed low to moderate  
554 cross-resistance to pyflubumide. From JPR, two selection lines (JPR-R1 and JPR-R2) were established  
555 by pyflubumide selection. SEL1 and SEL2 was the first and second generation of selection that finally  
556 generated the JPR-R1 strain. JPRR-R2 as selected out of JPR on plants as described in M&M.

557 **Fig. 2 The constitutive transcriptomic changes between JPO, JPR, JPR-R1, and JPR-R2. Panel**  
558 **A:** PCA plot of JPO, JPR, JPR-R1, and JPR-R2. The four samples of each strain are separately plotted.  
559 **Panel B:** Scatterplot of the differentially expressed genes in the two pyflubumide-resistant strains JPR-  
560 R1 and JPR-R2 versus ancestral JPR. Only the genes with an FDR-corrected *p*-value of < 0.05 and  
561  $\log_2\text{FC} \geq 1$  were regarded as differentially expressed. Only one cytochrome P450 was differentially  
562 transcribed in both pyflubumide-resistant strains, was down-regulated, and coded for CYP392A12. In  
563 panel B: Venn-diagram showing the overlap of differentially expressed genes in JPR-R1 and JPR-R2  
564 versus ancestral JPR. **Panel C:** Using JPO as the common reference, the transcriptional patterns of the  
565 three *k*-clustered groups of the 560 DEGs across JPR, JPR-R2, and JPR-R1 are plotted. Circles represent  
566 the average ( $\pm\text{SD}$ ) of gene-expression in each strain (color coded)


567 **Fig. 3 Timing of symptomology in *T. urticae* strains JPR, JPR-R1, and JPR-R2.** Percentage of mites  
568 that showed the symptoms of poisoning caused by pyflubumide treatment over 24 hours time course  
569 after spraying. Symptoms include death, inability to walk, or uncoordinated behavior (spastic  
570 movement) after a gentle touch by a tiny brush




571 **Fig. 4 The plastic transcriptomic changes upon 9 and 24 hours of exposure to a sub-lethal dose of**  
572 **pyflubumide. Panel A:** PCA plot of the individual samples alongside PC1 and PC2 (55.5% of total data  
573 variation) that were collected to investigate plastic transcriptomic responses. **Panel B:** Above, venn-  
574 diagram showing the overlap of differentially expressed genes in JPR-R1 and JPR-R2 after 24 h  
575 exposure to 100 mg/L pyflubumide. Below, scatterplot of the 109 shared differentially expressed genes  
576 in JPR-R1 and JPR-R2 exposed for 24 h to 100 mg/L pyflubumide. Genes that code for cytochrome


577 P450s are depicted by black circles and labelled with their CYP identifier. Only the genes with an FDR-  
578 corrected *p*-value of < 0.05 and  $\log_2\text{FC} \geq 1$  were regarded as differentially expressed


579

580



**A****C****B**



**A****B**